Marker Therapeutics (MRKR) Net Cash Flow (2010 - 2026)
Marker Therapeutics (MRKR) reported Net Cash Flow of -$1.4 million for Q1 2026, up 74.47% year-over-year from -$804852.9 in Q1 2025, and up 26.1% quarter-over-quarter from -$1.9 million in Q4 2025.
Marker Therapeutics (MRKR) Net Cash Flow (2010 - 2026) Analysis & Trends
Marker Therapeutics (MRKR) has 17 years of Net Cash Flow data on file, last reported at -$1.4 million in Q1 2026.
- Net Cash Flow for Q1 2026 came in at -$1.4 million, up 74.47% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.9 million (down 17.91% YoY), and the FY2025 annual result was -$2.1 million, down 152.67% from the prior year.
- Net Cash Flow advanced to -$1.4 million in Q1 2026 per MRKR's latest filing, from -$1.9 million in the prior quarter.
- Over five years, Net Cash Flow peaked at $10.2 million in Q4 2024 and troughed at -$14.7 million in Q1 2022.
- A 5-year average of -$1.6 million and a median of -$2.1 million in 2022 frame the typical range for Net Cash Flow.
- The sharpest annual moves came in 2023 and 2024: Net Cash Flow jumped 517.24% in 2023, then slumped 139.45% in 2024.
- A 5-year view of Net Cash Flow shows it stood at -$9.6 million in 2022, then increased by 12.07% to -$8.4 million in 2023, then jumped by 221.37% to $10.2 million in 2024, then sank by 118.64% to -$1.9 million in 2025, then rose by 26.1% to -$1.4 million in 2026.
- Business Quant data shows MRKR's Net Cash Flow at -$1.4 million in Q1 2026, -$1.9 million in Q4 2025, and $7.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | 2.44 Mn |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | 625.70 Mn |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | -2.44 Mn |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 457.40 Mn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | 664,983.53 |
| 10 | Marker Therapeutics | 28.20 Mn | 28.20 Mn | - | -1.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.40 Mn |
| Mar 31, 2026 | -1.40 Mn |
| Dec 31, 2025 | -1.90 Mn |
| Dec 31, 2025 | -1.90 Mn |
| Sep 30, 2025 | 7.13 Mn |
| Sep 30, 2025 | 7.13 Mn |
| Jun 30, 2025 | -1.88 Mn |
| Jun 30, 2025 | -1.88 Mn |
| Mar 31, 2025 | -5.50 Mn |
| Mar 31, 2025 | -5.50 Mn |
| Dec 31, 2024 | 10.19 Mn |
| Dec 31, 2024 | 10.19 Mn |
| Sep 30, 2024 | 1.20 Mn |
| Sep 30, 2024 | 1.20 Mn |
| Jun 30, 2024 | -3.52 Mn |
| Jun 30, 2024 | -3.52 Mn |
| Mar 31, 2024 | -3.79 Mn |
| Mar 31, 2024 | -3.79 Mn |
| Dec 31, 2023 | -8.40 Mn |
| Dec 31, 2023 | -8.40 Mn |